Bivalent HPV vaccine offers protection against HPV types
**Core Concept**
The bivalent Human Papillomavirus (HPV) vaccine is designed to protect against two high-risk HPV types, specifically types 16 and 18, which are responsible for a significant proportion of cervical cancer cases worldwide.
**Why the Correct Answer is Right**
The bivalent HPV vaccine works by inducing an immune response against these two HPV types, which are the most common cause of cervical cancer. The vaccine contains non-infectious virus-like particles (VLPs) that mimic the surface proteins of HPV types 16 and 18, eliciting an immune response that provides long-term protection against these types. The vaccine is administered in a series of doses to ensure optimal immunogenicity and efficacy.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because the bivalent HPV vaccine does not protect against HPV type 6 and 11, which are responsible for genital warts. The bivalent vaccine is specifically designed to target high-risk HPV types 16 and 18.
**Option B:** This option is incorrect because the bivalent HPV vaccine is not a monovalent vaccine, which would only protect against one HPV type. The bivalent vaccine offers protection against two types, making it a more effective tool in the prevention of cervical cancer.
**Option C:** This option is incorrect because the bivalent HPV vaccine is not a quadrivalent vaccine, which would offer protection against four different HPV types. The bivalent vaccine is specifically designed to target high-risk HPV types 16 and 18.
**Clinical Pearl / High-Yield Fact**
The bivalent HPV vaccine is an example of a targeted prevention strategy, where the vaccine is designed to protect against specific high-risk HPV types that are responsible for a significant proportion of cervical cancer cases. This approach has been shown to be effective in reducing the incidence of cervical cancer in vaccinated populations.
**Correct Answer: D. Types 16 and 18.**